ArticleJournal of the American Heart Association2023
Vessel Patency and Associated Factors of Drug-Coated Balloon for Femoropopliteal Lesion.
Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Drug-coated balloon combined with stent versus stent alone for femoropopliteal disease: a systematic review and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Twenty-Four-Month Outcomes of Intravascular Ultrasound-Guided Drug-Coated Balloon Angioplasty for Femoropopliteal Artery Disease.Journal of the American Heart Association · 2025Trial
- Two-year clinical outcomes of jetstream atherectomy followed by drug-coated balloon angioplasty for severely calcified femoropopliteal lesions.Heart and vessels · 2026Article
- Two-year clinical outcomes of jetstream atherectomy followed by drug-coated balloon angioplasty for severely calcified femoropopliteal lesions.Heart and vessels · 2026Article
- Clinical Impacts and Procedural Risks of Rotational Atherectomy for Heavily Calcified Femoropopliteal Lesions.JACC. Asia · 2026Article
- Contemporary outcomes of a DCB-based strategy with selective stent implantation for femoropopliteal artery lesions: results from the REAL-LEAD registry.CVIR endovascular · 2026Article
- Impact of 1-month dual antiplatelet therapy after treatment with drug-coated balloon for femoropopliteal artery disease.Heart and vessels · 2026Article
- Assessment of Recurrence Patterns and Treatment Strategies for Reintervention after Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Artery Diseases: Results of the ASTRA Study.Journal of atherosclerosis and thrombosis · 2026Article
- Temporal trends in device selection and clinical outcomes after femoropopliteal endovascular therapy: a multicenter real-world study.Cardiovascular intervention and therapeutics · 2026Article
- A Novel Guidewire Bias Modification Method for Atherectomy of Severely Calcified Femoropopliteal Lesion: JET BIAS.JACC. Case reports · 2026Article
- Directional Atherectomy Versus Plain Old Balloon Angioplasty for Vessel Preparation Before Drug-Coated Balloon Treatment in Moderate-to-Severe Calcified Lesions.Cardiovascular and interventional radiology · 2026Article
- Comparative Mid-Term Outcomes of Endovascular Strategies for Femoropopliteal Lesions Extending to the Distal Popliteal Artery.Cardiovascular and interventional radiology · 2026Article
- Paclitaxel distribution assessment after drug-coated balloon treatment in the superficial femoral artery: SNOW grade.Heart and vessels · 2026Article
- Outcomes of drug-coated balloon combined with stenting vs. stenting alone in the treatment of femoropopliteal artery lesions requiring bailout stenting.BMC surgery · 2026Article
- Three-year outcomes of the TCD-17187 (Kanshas) drug-coated balloon for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery.CVIR endovascular · 2026Article
- Timing of Restenosis and Reocclusion Following Endovascular Therapy for Femoropopliteal Lesions.Cureus · 2026Article
- Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Disrupt PAD III Observational Study.Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2026Observational
- Third Year in Review, Fourth Year in Preview, and the 2025Journal of the American Heart Association · 2026Article
- Endovascular Treatment for Femoropopliteal Arterial Lesions with a Focus on Long-Term Limb Prognosis.Annals of vascular diseases · 2026Review
- [Interventional revascularization combined with perforator composite flap for staged treatment of peripheral arterial disease with ankle soft tissue defects].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Although clinical trials have reported favorable outcomes after drug-coated balloon (DCB) therapy for femoropopliteal lesions, their real-world performance and predictors have not been well evaluated. This study aimed to elucidate 1-year freedom from restenosis and to explore the associated factors after a DCB for femoropopliteal lesions in clinical settings. Methods and Results This multicenter, prospective cohort registered 3165 de novo or restenotic femoropopliteallesions (mean lesion length, 13.5±9.3 cm; chronic total occlusion, 25.9%; severe calcification, 14.6%) that underwent successful DCB (Lutonix [24.2%] and IN.PACT Admiral [75.8%]) treatment between March 2018 and December 2019. Patency was assessed at 12±2 months. The primary outcome measure was 1-year freedom from restenosis and its associated factors. Bailout stenting was performed in 3.5% of patients. The postprocedural slow flow phenomenon was observed in 3.9% of patients. During a median follow-up of 14.2 months, 811 patients experienced restenosis. The Kaplan-Meier estimate of freedom from restenosis was 84.5% at 12 months (79.7% at 14 months). Focal, tandem, diffuse, and occlusive restenosis accounted for 37.4%, 9.8%, 18.9%, and 33.9%, respectively. Freedom from target lesion revascularization was 91.5% at 12 months. Risk factors independently associated with 1-year restenosis were a history of revascularization, smaller distal reference vessel diameter, severe calcification, chronic total occlusion, low-dose DCB, and residual stenosis. Conclusions The 1-year clinical outcomes after DCB use for femoropopliteal lesions in real-world practice was favorable. The additive risk factors were associated with a lower rate of freedom from restenosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.